Present at least two industries or stakeholders that would have been most disadvantaged by the Trans Pacific Partnership

In this paper a discussion will be carried out regarding any two industries or stakeholders which are
being most disadvantaged by the Trans Pacific Partnership. Trans Pacific Partnership (TPP) is a trade
agreement which has taken place between multiple countries including Australia, Brunei, Chile,
Canada, Malaysia, Japan, New Zealand, Mexico, Singapore, Peru, Vietnam and the United States.
This agreement which was signed by all the relevant parties in February 2016 has been the largest
trade agreement to have been signed ever. However there have been various areas which have been
identified as significantly affected due to this agreement which has been signed. One of such areas is
the price of the medicines and drugs, which are expected to shoot up significantly due to the
introduction of TPP and this in turn will create a lot of challenges for the people who are undergoing
some kind of treatment and may not be able to afford the costlier medicines.
It is expected that in the long run TPP will lead to limitation of the competition in the pharmaceutical
industry. This will lead to less than desired state of affairs for the industry where the larger and well
established entities will continue to enjoy a monopolistic power over the entire industry in view of
the fact there will not be any pressure from any new entrant in the industry. As has been mentioned
by Doctors Without Borders, "The TPP will still go down in history as the worst trade agreement for
access to medicines in developing countries." Also the TPP regulates the data protection for biologic
drugs. These drugs are structurally more complex as compared to the regular "small-molecule drugs"
and hence the effort and cost required to develop these are much higher. However the importance
of these is immense in view of the fact the drugs developed from the biological sources include anti-
toxins, vaccines, proteins, and monoclonal antibodies for everything from Ebola to cancer. In view
of the fact the costing of developing these drugs is costlier by 22 times as compared to the
nonbiologic drugs, the pharmaceutical companies have been trying to create "biosimilars" —
cheaper copies of the original drugs, similar to generic versions of pharmaceuticals.
As a result of the high pricing of the drugs, the entities in the industry are very keen for the...